News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
FDA
Swiss Approve Novartis International AG Drug For Blindness
August 29, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH (Reuters) - Drugmaker Novartis AG said on Tuesday that Switzerland had become the first European country to approve the company's Lucentis drug as a treatment for a leading cause of blindness in people over age 50.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
Europe
MORE ON THIS TOPIC
Drug pricing
Pharma’s Reluctance To Serve Europe To Dodge MFN Drug Pricing Is Chilling
April 2, 2026
·
3 min read
·
Annalee Armstrong
Job Trends
Innovation Pressure Cooker: Tackling Drug Discovery’s Biggest Challenges
April 2, 2026
·
5 min read
·
Angela Gabriel
Layoffs
Layoffs at Novo’s Ex-Catalent Site Despite Signs of Turnaround, Continued Investment
April 1, 2026
·
2 min read
·
Nick Paul Taylor
Approvals
Eli Lilly’s Oral Obesity Pill Approved, Kicking Off Renewed Novo Rivalry
April 1, 2026
·
3 min read
·
Heather McKenzie
